

## Vimta Labs Limited

Registered Office  
142, IDA Phase II, Cherlapally  
Hyderabad-500 051, Telangana, India  
T : +91 40 2726 4141  
F : +91 40 2726 3657



VLL\SE\031\2024-25  
Date: 17.07.2024

Listing Centre  
B S E Limited  
P J Towers, Dalal Street  
Mumbai: 400001  
**Scrip Code No.524394**

Asst Vice President  
National Stock Exchange of India Limited  
"Exchange Plaza", Bandra  
Kurla Complex, Bandra (E)  
Mumbai – 400051  
**Trading Symbol: VIMTALABS**

Dear Sir/Madam,

Sub – Press Release – Unaudited Financial Results – 30<sup>th</sup> June 2024.

Pursuant to Regulation 30 of SEBI (Listing obligations and disclosure requirements) 2015, please find attached the press release in connection with announcement of unaudited Standalone and Consolidated Financial Results for the 1<sup>st</sup> Quarter ended 30<sup>th</sup> June 2024.

This is for your information and records.

Thanking you,

Yours faithfully,  
for VIMTA LABS LIMITED

Sujani Vasireddi  
Company Secretary

Attachments: as above.



## Vimta Labs Limited Reports Q1 FY25 Results

**Q1 FY25 Total Income at Rs. 824 Mn,  
EBITDA margins at 30.6%; PAT margin at 14.9%**

**Hyderabad, July 17, 2024: Vimta Labs Limited (VIMTA)** (BSE: 524394, NSE: VIMTALABS), India's leading Contract Research and Testing Organisation, has announced its financial results for the quarter ended June 30, 2024.

### Consolidated Financial Results – Q1 FY25:

Particulars (Rs. Mn)	Q1 FY25	Q4 FY24	Q1 FY24
Total Income	824	802	841
EBITDA (including other income)	252	249	252
EBITDA Margin	30.6%	31.1%	30.0%
PAT	123	124	122
PAT Margin	14.9%	15.4%	14.5%
Basic EPS	5.5	5.6	5.5

**Commenting on results, Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited,** said: *"We are pleased to report stable business momentum with encouraging QoQ sales growth and stable EBITDA margins. Despite a challenging internal and external environment, we achieved a QoQ growth in sales, driven by Pharmaceutical services which demonstrated sustained growth, albeit slightly tempered by the other services.*

*Looking ahead, we are pleased to share that our new Life Sciences facility expansion will become operational in Q2 of this financial year. This facility is expected to play a significant role in driving our growth in the coming quarters. We remain optimistic about the future and are dedicated to fostering sustainable growth."*

### Key Result Highlights for the Q1 FY25 (Consolidated):

#### Q1 FY25

- ✓ Total Income for Q1 FY25 was at Rs. 824 Mn
- ✓ EBITDA for Q1 FY25 was Rs. 252 Mn; EBITDA margin was at 30.6%
- ✓ PBT for Q1 FY25 was at Rs. 165mn
- ✓ Q1 FY25 PAT was at Rs. 123 Mn; PAT margin was at 14.9%
- ✓ Basic EPS in Q1 FY25 was Rs. 5.5
- ✓ Total Debt as of 30<sup>th</sup> June 2024 stood at Rs. 130 Mn
- ✓ Cash and Cash equivalents were at Rs. 324 Mn as of 30<sup>th</sup> June 2024
- ✓ Q1 FY25 Capex spent was at Rs 164 Mn
- ✓ Debt to Equity ratio was 0.04x

**PRESS RELEASE**

For Immediate dissemination



**ABOUT VIMTA LABS LIMITED:**

Founded in 1984 with headquarters in Hyderabad, India, VIMTA LABS LTD., is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides clinical diagnostic services and environmental assessments and testing services.

**CAUTIONARY STATEMENT:**

*This press release may contain certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Vimta Labs Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.*

**For details, please contact:**

<b>Investor Relations at Vimta Labs</b> Narahai Naidu Dodda, CFO <a href="mailto:Narahai.Dodda@vimta.com">Narahai.Dodda@vimta.com</a>	<b>Registered Office</b> Plot Number 142, IDA Phase 2 Cherlapally, Hyderabad Telangana, India. 500051 CIN: L24110TG1990PLC011977 ISIN: INE579C01029 NSE Code: VIMTALABS BSE CODE: 524394 Website: <a href="http://www.vimta.com">www.vimta.com</a>
<b>Ernst &amp; Young</b> Mr. Siddesh Chawan <a href="mailto:Siddesh.Chawan@in.ey.com">Siddesh.Chawan@in.ey.com</a>	
Mr. Advait Bhadekar <a href="mailto:Advait.bhadekar@in.ey.com">Advait.bhadekar@in.ey.com</a>	